Case Study: a large pharmaceutical company achieves clearer FDA guidance for a complex generic injectable with Freyr

Large Pharmaceutical Company reduces FDA ambiguity with FREYR through 4-step engagement

The large pharmaceutical company, a developer of complex generics, faced persistent regulatory uncertainties and development hurdles for a generic injectable product. They engaged FREYR for strategic US FDA engagement services to help clarify expectations and derisk their program.

FREYR designed a targeted FDA interaction strategy, which included assessing key uncertainties, preparing comprehensive briefing packages, and facilitating productive meetings. This solution provided the client with clearer expectations and a refined development plan. FREYR's work minimized the risk of future submission deficiencies and turned scattered FDA interactions into a coherent engagement model for the client.